Published online before print September 27, 2001, doi: 10.1161/hh2001.097797
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2001 American Heart Association, Inc.
Molecular Medicine |
Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase
From Inotek Corporation (P.P., J.M., C.S.), Beverly, Mass, and the Department of Surgery (F.G.S., L.L., C.S.), New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ.
Correspondence to Csaba Szabó, MD, PhD, Inotek Corporation, Suite 419E, 100 Cummings Center, Beverly, MA 01915. E-mail szabocsaba{at}aol.com
Abstract—— Oxygen- and nitrogen-derived free radicals and oxidants play an important role in the pathogenesis of diabetic endothelial dysfunction. Recently we proposed the importance of oxidant-induced DNA strand breakage and activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic endothelial dysfunction. In this study, we tested whether established diabetic endothelial dysfunction is reversible by PARP inhibition. The novel PARP inhibitor PJ34 (10 mg/kg per day PO) was given at various lengths (4 weeks or 3 days) for established streptozotocin-diabetic animals. In addition, we also tested whether incubation of the aortic rings with PJ34 (3 µmol/L) or a variety of other PARP inhibitors for 1 hour affects the diabetic vascular changes. Both 4-week and 3-day PARP-inhibitor treatment of streptozotocin-diabetic mice with established endothelial dysfunction fully reversed the acetylcholine-induced endothelium-dependent relaxations in vitro. Furthermore, 1-hour in vitro incubation of aortae from streptozotocin-diabetic mice with various PARP inhibitors was able to reverse the endothelial dysfunction. ATP, NAD+, and NADPH levels were markedly reduced in diabetic animals, and PARP-inhibitor treatment was able to restore these alterations. Unexpectedly, pharmacological inhibition of PARP not only prevents the development of the endothelial dysfunction but is also able to rapidly reverse it. Thus, PARP activation and the associated metabolic compromise represent an ongoing process in diabetic blood vessels. Pharmacological inhibition of this process is able to reverse diabetic endothelial dysfunction.
Key Words: diabetes • endothelium • nitric oxide • necrosis • apoptosis
This article has been cited by other articles:
 |
|
 |
|
  S.-Y. Goh and M. E. Cooper The Role of Advanced Glycation End Products in Progression and Complications of Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Mathews and B. C. Berk PARP-1 Inhibition Prevents Oxidative and Nitrosative Stress-Induced Endothelial Cell Death via Transactivation of the VEGF Receptor 2 Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 711 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Radovits, J. Zotkina, L.-N. Lin, T. Bomicke, R. Arif, D. Gero, E. M. Horvath, M. Karck, C. Szabo, and G. Szabo Poly(ADP-Ribose) Polymerase Inhibition Improves Endothelial Dysfunction Induced by Hypochlorite Experimental Biology and Medicine, October 1, 2007; 232(9): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Eldor, A. Yeffet, K. Baum, V. Doviner, D. Amar, Y. Ben-Neriah, G. Christofori, A. Peled, J. C. Carel, C. Boitard, et al. Conditional and specific NF-{kappa}B blockade protects pancreatic beta cells from diabetogenic agents PNAS, March 28, 2006; 103(13): 5072 - 5077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Andrasi, A. Blazovics, G. Szabo, C. F. Vahl, and S. Hagl Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2972 - H2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, A. Vaslin, R. Benko, J. G. Mabley, L. Liaudet, G. Hasko, A. Marton, S. Batkai, M. Kollai, and C. Szabo A New, Potent Poly(ADP-ribose) Polymerase Inhibitor Improves Cardiac and Vascular Dysfunction Associated with Advanced Aging J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Young, D. Yu, R. M. Bateman, and G. B. Brock Oxidative Stress and Antioxidant Therapy: Their Impact in Diabetes-Associated Erectile Dysfunction J Androl, September 1, 2004; 25(5): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, N. J. Alp, S. Cai, C. A. Lygate, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Obrosova, F. Li, O. I. Abatan, M. A. Forsell, K. Komjati, P. Pacher, C. Szabo, and M. J. Stevens Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic Neuropathy Diabetes, March 1, 2004; 53(3): 711 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lohinai, J.G. Mabley, E. Feher, A. Marton, K. Komjati, and C. Szabo Role of the Activation of the Nuclear Enzyme Poly(ADP-Ribose) Polymerase in the Pathogenesis of Periodontitis Journal of Dental Research, December 1, 2003; 82(12): 987 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. El-Remessy, G. Abou-Mohamed, R. W. Caldwell, and R. B. Caldwell High Glucose-Induced Tyrosine Nitration in Endothelial Cells: Role of eNOS Uncoupling and Aldose Reductase Activation Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3135 - 3143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy Diabetes Care, May 1, 2003; 26(5): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhein, A. Kabat, A. Olbrich, P. Rosen, H. Schroder, and F.-W. Mohr Effect of Chronic Treatment with Vitamin E on Endothelial Dysfunction in a Type I in Vivo Diabetes Mellitus Model and in Vitro J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 114 - 122. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. E Cameron The aetiology of neuropathy in experimental diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 98 - 105. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Sheetz and G. L. King Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications JAMA, November 27, 2002; 288(20): 2579 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Szabo, A. Zanchi, K. Komjati, P. Pacher, A. S. Krolewski, W. C. Quist, F. W. LoGerfo, E. S. Horton, and A. Veves Poly(ADP-Ribose) Polymerase Is Activated in Subjects at Risk of Developing Type 2 Diabetes and Is Associated With Impaired Vascular Reactivity Circulation, November 19, 2002; 106(21): 2680 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.a. Pacher, L. Liaudet, J. G. Mabley, K. Komjati, and C. Szabo Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure J. Am. Coll. Cardiol., September 4, 2002; 40(5): 1006 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Virag and C. Szabo The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors Pharmacol. Rev., September 1, 2002; 54(3): 375 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, L. Liaudet, P. Bai, L. Virag, J. G. Mabley, G. Hasko, and C. Szabo Activation of Poly(ADP-Ribose) Polymerase Contributes to Development of Doxorubicin-Induced Heart Failure J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, L. Liaudet, F. G. Soriano, J. G. Mabley, E. Szabo, and C. Szabo The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes Diabetes, February 1, 2002; 51(2): 514 - 521. [Abstract] [Full Text] [PDF]
|
|